LYNPARZA (AstraZeneca Pty Ltd)
Product name
LYNPARZA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
240 (255 working days)
Active ingredients
olaparib
Registration type
EOI
Indication
Prostate cancer
LYNPARZA (tablet) is now also indicated as monotherapy for the
- treatment of adult patients with BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer who have progressed following prior therapy that included a new hormonal agent. BRCA mutation status should be determined by an experienced laboratory using a validated test method.